The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.

Sweats

Revised text to state that three-quarters of men with locally advanced or metastatic prostate cancer treated with medical or surgical orchiectomy experience hot flashes.

Revised text to include aromatase inhibitors as a drug-associated cause of sweats.

Revised text to state that the optimal dose of venlafaxine to reduce the severity and intensity of hot flashes is 75 mg of the extended-release formulation daily.

Revised text to include gabapentin 300 mg 3 times per day as a treatment option for men with prostate cancer who experience hot flashes (cited Loprinzi et al. as reference 41).

Back to Top

< Previous Section  |  Next Section >